Meric Sengoz, Ufuk Abacioglu, İlknur Cetin, Levent Turkeri

Slides:

Advertisements

Similar presentations

Volume 53, Issue 3, Pages (March 2008)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 43, Issue 5, Pages (May 2003)

Volume 50, Issue 1, Pages (July 2006)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 4, Issue 5, Pages (September 2017)

Testosterone Therapy in Men With Prostate Cancer

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 70, Issue 6, Pages (December 2016)

Prostate Cancer: Highlights from 2006

Volume 54, Issue 4, Pages (October 2008)

Volume 53, Issue 5, Pages (May 2008)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 72, Issue 5, Pages (November 2017)

Volume 43, Issue 5, Pages (May 2003)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

What is New in Hormone Therapy for Prostate Cancer in 2007?

Volume 53, Issue 4, Pages (April 2008)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 56, Issue 2, Pages (August 2009)

Obesity and Prostate Cancer: A Role for Adipokines

Counselling the Prostate Cancer Patient

Volume 64, Issue 6, Pages (December 2013)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Rapid Progression of Advanced “Hormone-Resistant” Prostate Cancer During Palliative Treatment with Progestins for Cancer Cachexia Davide Tassinari, MD,

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 65, Issue 6, Pages (June 2014)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Optimising Hormone Therapy in Advanced Disease

Prostate Specific Antigen Doubling Time as Auxiliary End Point in Hormone Refractory Prostatic Carcinoma Hans-Peter Schmid, Rudolf Morant, Jürg Bernhard,

Antonio Alcaraz, Pierre Teillac European Urology Supplements

What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,

Testicular Cancer Variations in Time and Space in Europe

Neal Shore European Urology Supplements

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Long-Term Hormonal Therapy: Who Would Benefit?

PSA Levels and the Probability of Prostate Cancer on Biopsy

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Thomas Steuber, Matthew Frank O'Brien, Hans Lilja European Urology

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Richard Berges European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients Kurt Miller European Urology Supplements Volume.

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Manfred Wirth, Peter Iversen, David McLeod, William See

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Epidemiology and Demographics of Prostatitis

Does PSA Testing Influence the Natural History of Prostate Cancer?

Volume 51, Issue 5, Pages (May 2007)

Introduction European Urology Supplements

Presentation transcript:

PSA Bouncing after External Beam Radiation for Prostate Cancer with or without Hormonal Treatment Meric Sengoz, Ufuk Abacioglu, İlknur Cetin, Levent Turkeri European Urology Volume 43, Issue 5, Pages 473-477 (May 2003) DOI: 10.1016/S0302-2838(03)00138-6

Fig. 1 Magnitude of monthly PSA rises in bouncers with or without hormonal treatment (HT) plotted against the time of bouncing (excluding the case with a monthly PSA rise of 3.45ng/ml in the third month). European Urology 2003 43, 473-477DOI: (10.1016/S0302-2838(03)00138-6)